CSF3 and cancer: While prior studies used data prior to 2011 and reported underutilization of G-CSF among patients with cancer receiving high–FN risk regimens,8,29 our study showed a gradual increase in G-CSF use among patients receiving high–FN risk regimens in the past 5 years in both populations.